Who developed mitotane and where is its manufacturer?

Mitotane (Mitotane is manufactured by Bristol Myers Squibb, but it is marketed as an orphan drug for the treatment of adrenocortical cancer due to the small number of patients who need it. Its primary use is in patients who have persistent disease despite surgical resection, those who are not candidates for surgery, or those with metastatic disease. In a 2007 retrospective study of 177 patients from 1985 to 2005, the recurrence-free interval was significantly increased with mitotane after radical surgery compared with surgery alone.

Mitotan, sold under the brand nameLysodren, is a steroidogenesis inhibitor and cytostatic antineoplastic drug used to treat adrenocortical carcinoma and Cushing's syndrome. It is a derivative of the early pesticide DDT and an isomer of p'-DDDTooltip dichlorodiphenyldichloroethane, also known as 2,4'-(dichlorodiphenyl)-2,2-dichloroethane. The most common side effects of mitotane are difficulty with motor coordination, paresthesias, dizziness, drowsiness, mucositis, vomiting, diarrhea, nausea, perigastric discomfort, rash, muscle weakness, adrenal insufficiency, loss of appetite, fatigue, gynecomastia, and confusion.

The original drug of mitotane has been launched in China, but it has only been on the market for a short time, its purchase is very difficult, and it is not included in medical insurance. Mitotane marketed overseas The original drug has European and Turkish versions, specificationsThe price of 500mg*100 tablets per box may be more than 9,000 yuan (the price may fluctuate due to exchange rates). Mitotan generic drugs are also sold overseas, and their drug ingredients are basically the same as those of the original drug. For example, the specifications produced by Laos pharmaceutical factoriesThe price of 500mg*100 tablets per box may be more than 3,000 yuan (prices may fluctuate due to exchange rates).